CANF
Price
$2.21
Change
+$0.05 (+2.31%)
Updated
Sep 28, 04:59 PM (EDT)
Capitalization
4.87M
Intraday BUY SELL Signals
NIKI
Price
$4.71
Change
+$0.09 (+1.95%)
Updated
Sep 28, 04:18 PM (EDT)
Capitalization
3.88M
Intraday BUY SELL Signals
Interact to see
Advertisement

CANF vs NIKI

CANF vs NIKI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CANF vs. NIKI commentary
Sep 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Buy and NIKI is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CANF vs NIKI: Fundamental Ratings
CANF
NIKI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
9094
P/E GROWTH RATING
1..100
10020
SEASONALITY SCORE
1..100
2485

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (13) in the Biotechnology industry is in the same range as NIKI (44) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to NIKI’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NIKI (100) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to NIKI’s over the last 12 months.

NIKI's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as CANF (100) in the Biotechnology industry. This means that NIKI’s stock grew similarly to CANF’s over the last 12 months.

CANF's Price Growth Rating (90) in the Biotechnology industry is in the same range as NIKI (94) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to NIKI’s over the last 12 months.

NIKI's P/E Growth Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for CANF (100) in the Biotechnology industry. This means that NIKI’s stock grew significantly faster than CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFNIKI
RSI
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
81%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
MACD
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 14 days ago
86%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
COMPARISON
Comparison
Sep 28, 2026
Stock price -- (CANF: $2.16 vs. NIKI: $4.62)
Brand notoriety: CANF and NIKI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 6% vs. NIKI: 40%
Market capitalization -- CANF: $4.87M vs. NIKI: $3.88M
CANF [@Biotechnology] is valued at $4.87M. NIKI’s [@Biotechnology] market capitalization is $3.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green while NIKI’s FA Score has 1 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • NIKI’s FA Score: 1 green, 4 red.
According to our system of comparison, NIKI is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 4 TA indicator(s) are bullish while NIKI’s TA Score has 4 bullish TA indicator(s).

  • CANF’s TA Score: 4 bullish, 5 bearish.
  • NIKI’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NIKI is a better buy in the short-term than CANF.

Price Growth

CANF (@Biotechnology) experienced а -3.48% price change this week, while NIKI (@Biotechnology) price change was -2.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.98%. For the same industry, the average monthly price growth was -7.12%, and the average quarterly price growth was +4.53%.

Industries' Descriptions

@Biotechnology (+0.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CANF
Daily Signal:
Gain/Loss:
NIKI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JBI4.210.09
+2.18%
Janus International Group
PAVS4.420.08
+1.84%
Paranovus Entertainment Technology Ltd
RVTY151.110.43
+0.29%
Revvity
DAC154.14-0.52
-0.34%
Danaos Corp
RFIL8.28-0.03
-0.36%
RF Industries Ltd

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been closely correlated with APVO. These tickers have moved in lockstep 95% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.37%
APVO - CANF
95%
Closely correlated
+3.28%
GNPX - CANF
93%
Closely correlated
-6.53%
ICU - CANF
91%
Closely correlated
-0.58%
MLEC - CANF
89%
Closely correlated
-2.69%
LONA - CANF
78%
Closely correlated
-34.87%
More

NIKI and

Correlation & Price change

A.I.dvisor indicates that over the last year, NIKI has been loosely correlated with HLSQ. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NIKI jumps, then HLSQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NIKI
1D Price
Change %
NIKI100%
-8.70%
HLSQ - NIKI
60%
Loosely correlated
N/A
CANF - NIKI
48%
Loosely correlated
-0.37%
APVO - NIKI
46%
Loosely correlated
+3.28%
ICU - NIKI
45%
Loosely correlated
-0.58%
MLEC - NIKI
45%
Loosely correlated
-2.69%
More